Simplex Trading, LLC Cue Biopharma, Inc. Transaction History

Simplex Trading, LLC

$2.81 Billion
Q3 2024

A detailed history of Simplex Trading, LLC transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 4,056 shares of CUE stock, worth $4,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,056

Holding current value

$4,380

% of portfolio

0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$0.45 - $1.08 $1,825 - $4,380	4,056 New	4,056 $3,000
Q1 2024 Apr 25, 2024	BUY	$1.77 - $3.09 $16,869 - $29,450	9,531 New	9,531 $18,000
Q3 2023 Nov 01, 2023	BUY	$2.23 - $4.69 $49,766 - $104,666	22,317 New	22,317 $51,000
Q1 2023 Apr 27, 2023	BUY	$2.41 - $3.74 $27,922 - $43,331	11,586 New	11,586 $41,000
Q3 2022 Nov 04, 2022	SELL	$2.23 - $3.37 $3,166 - $4,785	-1,420 Reduced 7.97%	16,400 $36,000
Q2 2022 Aug 03, 2022	BUY	$2.49 - $5.92 $37,357 - $88,817	15,003 Added 532.59%	17,820 $44,000
Q1 2022 May 02, 2022	SELL	$4.41 - $12.28 $38,446 - $107,057	-8,718 Reduced 75.58%	2,817 $13,000
Q4 2021 Feb 23, 2022	BUY	$10.86 - $17.85 $44,786 - $73,613	4,124 Added 55.65%	11,535 $130,000
Q3 2021 Oct 28, 2021	BUY	$10.06 - $15.3 $6,036 - $9,180	600 Added 8.81%	7,411 $90,000
Q2 2021 Aug 12, 2021	SELL	$10.9 - $14.53 $33,899 - $45,188	-3,110 Reduced 31.35%	6,811 $79,000
Q1 2021 Apr 26, 2021	BUY	$11.2 - $16.09 $111,115 - $159,628	9,921 New	9,921 $121,000
Q3 2020 Oct 14, 2020	SELL	$15.05 - $23.54 $6,712 - $10,498	-446 Closed	0 $0
Q2 2020 Jul 13, 2020	SELL	$12.7 - $30.73 $6,832 - $16,532	-538 Reduced 54.67%	446 $0
Q1 2020 Apr 29, 2020	BUY	$9.85 - $22.27 $9,692 - $21,913	984 New	984 $13,000

Others Institutions Holding CUE

# of Institutions

Shares Held

14.1M

Call Options Held

14.4K

Put Options Held

2.6K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account